A Phase 3 interventional study of Gemcitabine and Cisplatin in Cancer of Cervix, sponsored by Eli Lilly and Company. Completed at 7 sites in 7 countries. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2009-08-11.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing gemcitabine in Uterine Cervical Neoplasms — 4 open to participants now, 4 under way, 3 of them phase 3. Gemcitabine · Uterine Cervical Neoplasms.
Among the 18 studies testing gemcitabine in Uterine Cervical Neoplasms, this one has the largest enrollment of the 16 interventional ones that give a count, is the only one that started in 2002, is one of 8 in phase 3, and was the 6th registered.
2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 680 are open to participants now.
Browse Uterine Cervical Neoplasms studies →4 of the 18 studies testing gemcitabine in Uterine Cervical Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Hospital do Coracao · Sites in Brazil
Ages 18–70 · Women only
Chuangzhen Chen · Sites in China
Ages 18–70 · Women only
National Institute of Cancerología · Sites in Mexico
Ages 18+ · Women only
National Institute of Cancerología · Sites in Mexico
Ages 18–70 · Women only
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 8
First in 1999; this study’s year is marked. 1 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 515 is above the median of 100 across 1,740 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 95 across the 16 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 18 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Eli Lilly and Company has 6 studies filed under Uterine Cervical Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies testing gemcitabine in Uterine Cervical Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06156514Phase 3National Institute of CancerologíaEvaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer | 2026-11-30 |
| NCT05764044Phase 3Hospital do CoracaoAdjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies testing gemcitabine in Uterine Cervical Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the effectiveness of two methods of treating cancer of the cervix. Half the patients will receive gemcitabine plus cisplatin while undergoing radiation therapy, followed by adjuvant gemcitabine and cisplatin and the other half will receive cisplatin along with radiation therapy without adjuvant therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Gemcitabine 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks Brachytherapy, 30-35 Gy over 1 week Two week rest period with no chemotherapy or radiation Cisplatin, 50 mg/m2, intravenous (IV), day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles
Drug: Gemcitabine · Drug: Cisplatin · Radiation: Brachytherapy · Radiation: Pelvic radiation
Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks Brachytherapy, 30-35 Gy over 1 week
Drug: Cisplatin · Radiation: Brachytherapy · Radiation: Pelvic radiation
Also known as: LY188011, Gemzar
Brachytherapy, 30-35 Gy over 1 week
Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
Number of Participants With Progressive Disease or Death Due to Any Cause at 3 Years
Original outcome was Progression-Free Survival (PFS) probability at 3 years. PFS=time from baseline to progressive disease (PD) or death from any cause. Probability is not an accepted "Measure Type", so number of progression-free patients still at risk and cumulative number of patients that had an event (PD or death of any cause) are presented.
Time frame: Tumor assessments at baseline, weekly during chemoradiation & brachytherapy, on Day 1 of adjuvant Cycles 1&2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively
Number of Participants With Progressive Disease or Death Due to Disease Under Study at Various Time Points
Original outcome was Time to Progressive Disease (TTPD), which is the time from baseline to event (progressive disease or death due to study disease). The median TTPD was not achieved and therefore the cumulative number of participants with event (and those still at risk) at various time points are presented.
Time frame: Tumor assessments at baseline, weekly during chemoradiation & brachytherapy, on Day 1 of adjuvant Cycles 1&2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively
Local Failure Rate
Local failure rate (LFR) was defined as the the proportion of per-protocol participants who had progressive disease (PD) in the cervix or pelvis. LFR = The number of (a) participants who progressed in the cervix or pelvis divided by (b) the number of participants in each arm. (LFR=a/b).
Time frame: Tumor assessments at baseline, weekly during chemoradiation & brachytherapy, on Day 1 of adjuvant Cycles 1&2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively
Tumor Response
Tumor response rate (TRR) defined as number of qualified responder patients with confirmed complete or partial response.
Time frame: Tumor assessments at baseline, weekly during chemoradiation & brachytherapy, on Day 1 of adjuvant Cycles 1&2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively
Number of Participants Who Died From Any Cause at Various Time Points
Original outcome was Overall Survival, which was defined as time from baseline to death from any cause.
Time frame: baseline to date of death from any cause (includes 60 month follow-up period)
Number of Participants With Progressive Disease or Death Due to Any Cause at Various Time Points
Original outome was Progression-Free Survival, which was defined as time from baseline to progressive disease or death due to any cause.
Time frame: Tumor assessments at baseline, weekly during chemoradiation & brachytherapy, on Day 1 of adjuvant Cycles 1&2 for Arm A, at the 30-day post-study visit, every 4/6 months for 12/48 months of the short/long post-study follow-up periods respectively
| Milestone | Gemcitabine/Cisplatin/Radiation | Cisplatin/Radiation |
|---|---|---|
| Started | 259 | 256 |
| Completed | 217 | 244 |
| Not completed | 42 | 12 |
| Withdrew: Adverse event | 18 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Patient moved | 0 | 1 |
| Withdrew: Withdrawal by subject | 9 | 3 |
| Withdrew: Protocol entry criteria not met | 2 | 1 |
| Withdrew: Clinical relapse | 2 | 1 |
| Withdrew: Lack of efficacy, progressive disease | 1 | 2 |
| Withdrew: Lack of efficacy, stable disease | 1 | 0 |
| Withdrew: Physician decision | 3 | 1 |
| Withdrew: Death from study drug toxicity | 2 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Death from other cause | 1 | 0 |
| Withdrew: Reason not specified | 0 | 1 |
Original outcome was Progression-Free Survival (PFS) probability at 3 years. PFS=time from baseline to progressive disease (PD) or death from any cause. Probability is not an accepted "Measure Type", so number of progression-free patients still at risk and cumulative number of patients that had an event (PD or death of any cause) are presented.
| participants | Gemcitabine/Cisplatin/Radiation | Cisplatin/Radiation |
|---|---|---|
| 3 Years: Number of Patients with Event | 55 | 83 |
| 3 Years: Number of Patients at Risk | 149 | 141 |
Original outcome was Time to Progressive Disease (TTPD), which is the time from baseline to event (progressive disease or death due to study disease). The median TTPD was not achieved and therefore the cumulative number of participants with event (and those still at risk) at various time points are presented.
| participants | Gemcitabine/Cisplatin/Radiation | Cisplatin/Radiation |
|---|---|---|
| 3 Months: Number of Patients with Event | 5 | 8 |
| 3 Months: Number of Patients at Risk | 221 | 238 |
| 6 Months: Number of Patients with Event | 10 | 25 |
| 6 Months: Number of Patients at Risk | 204 | 218 |
| 12 Months: Number of Patients with Event | 21 | 44 |
| 12 Months: Number of Patients at Risk | 186 | 195 |
| 18 Months: Number of Patients with Event | 24 | 62 |
| 18 Months: Number of Patients at Risk | 176 | 170 |
| 24 Months: Number of Patients with Event | 31 | 69 |
| 24 Months: Number of Patients at Risk | 167 | 158 |
| 36 Months: Number of Patients with Event | 40 | 78 |
| 36 Months: Number of Patients at Risk | 149 | 141 |
Local failure rate (LFR) was defined as the the proportion of per-protocol participants who had progressive disease (PD) in the cervix or pelvis. LFR = The number of (a) participants who progressed in the cervix or pelvis divided by (b) the number of participants in each arm. (LFR=a/b).
| proportion of participants with PD | Gemcitabine/Cisplatin/Radiation | Cisplatin/Radiation |
|---|---|---|
| Local Failure Rate | 0.113 | 0.166 |
Tumor response rate (TRR) defined as number of qualified responder patients with confirmed complete or partial response.
| participants | Gemcitabine/Cisplatin/Radiation | Cisplatin/Radiation |
|---|---|---|
| Complete Response | 223 | 217 |
| Partial Response | 22 | 20 |
Original outcome was Overall Survival, which was defined as time from baseline to death from any cause.
| participants | Gemcitabine/Cisplatin/Radiation | Cisplatin/Radiation |
|---|---|---|
| 3 Months: Number of Patients with Event | 3 | 0 |
| 3 Months: Number of Patients at Risk | 253 | 254 |
| 6 Months: Number of Patients with Event | 9 | 4 |
| 6 Months: Number of Patients at Risk | 241 | 248 |
| 12 Months: Number of Patients with Event | 22 | 25 |
| 12 Months: Number of Patients at Risk | 226 | 222 |
| 18 Months: Number of Patients with Event | 33 | 46 |
| 18 Months: Number of Patients at Risk | 207 | 195 |
| 24 Months: Number of Patients with Event | 39 | 58 |
| 24 Months: Number of Patients at Risk | 200 | 182 |
| 36 Months: Number of Patients with Event | 53 | 75 |
| 36 Months: Number of Patients at Risk | 175 | 158 |
Original outome was Progression-Free Survival, which was defined as time from baseline to progressive disease or death due to any cause.
| participants | Gemcitabine/Cisplatin/Radiation | Cisplatin/Radiation |
|---|---|---|
| 3 Months: Number of Patients with Event | 8 | 8 |
| 3 Months: Number of Patients at Risk | 221 | 238 |
| 6 Months: Number of Patients with Event | 14 | 25 |
| 6 Months: Number of Patients at Risk | 204 | 218 |
| 12 Months: Number of Patients with Event | 29 | 45 |
| 12 Months: Number of Patients at Risk | 186 | 195 |
| 18 Months: Number of Patients with Event | 34 | 63 |
| 18 Months: Number of Patients at Risk | 176 | 170 |
| 24 Months: Number of Patients with Event | 42 | 72 |
| 24 Months: Number of Patients at Risk | 167 | 158 |
| 36 Months: Number of Patients with Event | 55 | 83 |
| 36 Months: Number of Patients at Risk | 149 | 141 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gemcitabine/Cisplatin/Radiation | — | — | — |
| Cisplatin/Radiation | — | — | — |
| Event | Gemcitabine/Cisplatin/Radiation | Cisplatin/Radiation |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 15/260 | 3/255 |
| ThrombocytopeniaBlood and lymphatic system disorders | 9/260 | 0/255 |
| AnaemiaBlood and lymphatic system disorders | 6/260 | 0/255 |
| Febrile neutropeniaBlood and lymphatic system disorders | 6/260 | 1/255 |
| VomitingGastrointestinal disorders | 6/260 | 4/255 |
| HypokalaemiaMetabolism and nutrition disorders | 6/260 | 1/255 |
| Vaginal haemorrhageReproductive system and breast disorders | 5/260 | 5/255 |
| HyponatraemiaMetabolism and nutrition disorders | 5/260 | 1/255 |
| Abdominal painGastrointestinal disorders | 4/260 | 1/255 |
| ProctitisGastrointestinal disorders | 4/260 | 0/255 |
| Event | Gemcitabine/Cisplatin/Radiation | Cisplatin/Radiation |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 193/260 | 74/255 |
| AnaemiaBlood and lymphatic system disorders | 175/260 | 115/255 |
| NauseaGastrointestinal disorders | 167/260 | 155/255 |
| Vaginal haemorrhageReproductive system and breast disorders | 148/260 | 157/255 |
| DiarrhoeaGastrointestinal disorders | 159/260 | 131/255 |
| VomitingGastrointestinal disorders | 146/260 | 121/255 |
| LeukopeniaBlood and lymphatic system disorders | 145/260 | 114/255 |
| DysuriaRenal and urinary disorders | 95/260 | 80/255 |
| Abdominal painGastrointestinal disorders | 87/260 | 57/255 |
| FatigueGeneral disorders | 80/260 | 57/255 |
| Age Continuous(years) | Gemcitabine/Cisplatin/Radiation | Cisplatin/Radiation | Total |
|---|---|---|---|
| Mean | 45.8 ± 9.8 | 46.5 ± 9.2 | 46.1 ± 9.5 |
| Sex: Female, Male(Participants) | Gemcitabine/Cisplatin/Radiation | Cisplatin/Radiation | Total |
|---|---|---|---|
| Female | 259 | 256 | 515.0 |
| Male | 0 | 0 | 0.0 |
| Region of Enrollment(participants) | Gemcitabine/Cisplatin/Radiation | Cisplatin/Radiation | Total |
|---|---|---|---|
| Pakistan | 27 | 29 | 56.0 |
| Mexico | 28 | 31 | 59.0 |
| Argentina | 17 | 18 | 35.0 |
| Thailand | 34 | 33 | 67.0 |
| Peru | 29 | 31 | 60.0 |
| India | 60 | 56 | 116.0 |
| Bosnia and Herzegovina | 33 | 28 | 61.0 |
| Panama | 31 | 30 | 61.0 |
| Grade of Histological Diagnosis(participants) | Gemcitabine/Cisplatin/Radiation | Cisplatin/Radiation | Total |
|---|---|---|---|
| Moderately Differentiated | 114 | 119 | 233.0 |
| Poorly Differentiated | 48 | 44 | 92.0 |
| Unknown | 69 | 69 | 138.0 |
| Undifferentiated | 2 | 0 | 2.0 |
| Well Differentiated | 26 | 24 | 50.0 |
| Karnofsky Performance Status Scale(participants) | Gemcitabine/Cisplatin/Radiation | Cisplatin/Radiation | Total |
|---|---|---|---|
| Unknown (Missing) | 1 | 0 | 1.0 |
| 70 - Unable to carry on normal activity | 0 | 1 | 1.0 |
| 80 - Activity with effort; some signs of disease | 8 | 9 | 17.0 |
| 90 - Normal activity; minor signs of disease | 147 | 145 | 292.0 |
| 100 - Normal no complaints; no evidence of disease | 103 | 101 | 204.0 |
| Pathological Diagnosis(participants) | Gemcitabine/Cisplatin/Radiation | Cisplatin/Radiation | Total |
|---|---|---|---|
| Adenocarcinoma of Cervix | 17 | 15 | 32.0 |
| Adeno/Squamous Cell Carcinoma | 198 | 199 | 397.0 |
| Other - Poorly Differentiated Carcinoma | 1 | 0 | 1.0 |
| Other - Squamous | 43 | 42 | 85.0 |
| Race/Ethnicity(participants) | Gemcitabine/Cisplatin/Radiation | Cisplatin/Radiation | Total |
|---|---|---|---|
| Western Asian | 87 | 85 | 172.0 |
| Caucasian | 33 | 29 | 62.0 |
| East/Southeast Asian | 34 | 33 | 67.0 |
| Hispanic | 105 | 109 | 214.0 |
| Stage of Disease(participants) | Gemcitabine/Cisplatin/Radiation | Cisplatin/Radiation | Total |
|---|---|---|---|
| Stage IIIA | 1 | 1 | 2.0 |
| Stage IIIB | 94 | 94 | 188.0 |
| Stage IIB | 160 | 156 | 316.0 |
| Stage IVA | 4 | 5 | 9.0 |
2 further baseline measures are reported on the registry.
The record gives a start of May 2002, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gemcitabine